Gold could slump another 20% by September, says Citi — here’s why
Since the outbreak of the U.S.-Iran war on Feb. 28, gold’s reputation as a “safe haven” asset in times of turmoil has come under pressure.
India’s growth story faces its toughest test yet in Modi’s third term
Prime Minister Narendra Modi faces his biggest test as India’s appeal as the world’s fastest-growing economy dims for global investors.
Indonesia raises rates in surprise move as rupiah lingers near record lows
In a statement, the central bank said this was also a “pre-emptive measure” to maintain inflation within the government’s target range of 1.5% to 3.5%.
Trump repeats claims that Iran deal is only ‘days’ away, despite recent strikes
Speaking to reporters after attending the NBA Finals in New York, Trump said the two parties are in the final stages of a “very, very good deal”.
The space race is coming for pharma: Why drug development is heading to lower Earth orbit
Companies see a commercial opportunity in creating new ways to administer drugs to patients – in space.
Electric vehicle giant BYD predicts 80% of China car sales will soon be electric
BYD expects China’s competitive electric vehicle market to continue growing, even as manufacturers and analysts anticipate domestic demand to taper further.
CNBC Daily Open: Hat trick of tech IPOs complete with OpenAI filing
OpenAI confidentially files for IPO, adding to a blockbuster tech line-up as the AI giant joins Anthropic and SpaceX in going to market.
Iraq and UAE race to establish alternative oil pipelines as exports through Hormuz dry up
Last week, the Iraqi cabinet approved plans to accelerate crude exports through the Kurdistan-Turkey pipeline network.
BlackRock says ‘mega forces’ are changing investing. Here’s what they say to do
Investors may need to rethink the most basic principles of portfolio management as AI changes the rules, according to BlackRock.
Nuvalent shares surge 39% after UK’s GSK agrees to buy the cancer drugmaker for $10.6 billion
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers’ race to bolster pipelines.
